TIEFENBACHER marks 'World Cancer Day 2023' to increase awareness prevention throughout media together

TIEFENBACHER joined to harness the power of social media to raise awareness on cancer early detection and prevention. Furthermore we support cancer survivors and build cancer care capacity for people. These efforts are also a contribution to reduce the global burden of cancer.

“World Cancer Day every 4 February  is the global uniting initiative led by the Union for International Cancer Control (UICC). By raising worldwide awarness, we collective resonate against the cancer burden in the world. Undoubtedly Cancer has a global impact of around 20 million new cases each year, remaining a major public health challenge. In the fight against this disease, we are committed to delivering better affordable medicines for cancer patients around the world.

Hereby we are always aiming to improve patients’ lives by developing added value medicines with a better posology, additional strengths, and suitable fixed dosage combinations. Although we offer personalized therapies by combining medicines with smart e-health solutions – just to name a few of our differentiated and innovative product solutions.

Additionally TIEFENBACHER PHARMACEUTICALS (FDF business unit of TIEFENBACHER GROUP) has already 25 leading highly potent cancer drugs in its launch pipeline. Certainly these are planned to be developed and manufactured in our new state-of-the-art high potent facilities in Hyderabad.

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).  

For more information about our finished dosage forms and healthcare solutions, please contact AET Tiefenbacher Pharmaceuticals: info@aet.eu or please visit us on: www.tiefenbacher-pharmaceuticals.com

About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on:  www.tiefenbachergroup.com